For the quarter ending 2026-03-31, CHRS made $12,310K in revenue. -$38,327K in net income. Net profit margin of -311.35%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net revenue | 12,310 | 12,748 | 11,571 | 10,254 |
| Cost of goods sold | 3,814 | 4,045 | 3,721 | 3,395 |
| Research and development | 21,543 | 30,974 | 27,252 | 26,306 |
| Selling, general and administrative | 23,104 | 23,609 | 24,931 | 26,039 |
| Total costs and expenses | 48,461 | 58,628 | 55,904 | 55,740 |
| Loss from operations | -36,151 | -45,880 | -44,333 | -45,486 |
| Interest expense | 2,186 | 2,249 | 2,325 | 2,277 |
| Loss on debt extinguishment | - | 0 | - | - |
| Other income (expense), net | 1,402 | 1,782 | 2,141 | 2,901 |
| Loss from continuing operations before income taxes | -36,935 | -46,347 | -44,517 | -44,862 |
| Net loss from continuing operations | -36,935 | -46,347 | -44,517 | -44,862 |
| Net revenue | -899 | 25,978* | 10,663 | - |
| Cost of goods sold | 55 | 16,503* | 287 | - |
| Research and development | - | -985* | 564 | - |
| Selling, general and administrative | 50 | 7,567* | 326 | - |
| Total costs and expenses | 105 | 23,084* | 1,177 | - |
| Income from operations | -1,004 | 2,894* | 9,486 | - |
| Interest expense | - | 2,023* | - | - |
| Gain on sale transactions, net | -388 | -886* | -422 | - |
| Gain on debt extinguishment | - | 20,572* | - | - |
| Other income (expense), net | - | -11,852* | -78 | - |
| Net income from discontinued operations before income taxes | -1,392 | 8,704 | 8,986 | - |
| Net loss from discontinued operations, net of tax (note 6) | -1,392 | 8,704 | 8,986 | 342,629 |
| Net gain | -38,327 | -37,643 | -35,531 | 297,767 |
| Basic EPS | -0.28 | -0.313 | -0.31 | 2.57 |
| Diluted EPS | -0.28 | -0.313 | -0.31 | 2.57 |
| Basic Average Shares | 136,398,303 | 120,409,168 | 116,229,170 | 116,077,710 |
| Diluted Average Shares | 136,398,303 | 120,409,168 | 116,229,170 | 116,077,710 |
Coherus Oncology, Inc. (CHRS)
Coherus Oncology, Inc. (CHRS)